# Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene

> **NCT02237937** · PHASE4 · UNKNOWN · sponsor: **HolsboerMaschmeyer NeuroChemie GmbH** · enrollment: 80 (estimated)

## Conditions studied

- Major Depression

## Interventions

- **DRUG:** Paroxetine
- **DRUG:** Sertraline
- **DRUG:** Citalopram
- **DRUG:** Venlafaxine
- **DRUG:** Amitriptyline
- **DRUG:** Escitalopram
- **DRUG:** Amitriptylinoxide
- **DRUG:** Nortriptyline
- **DRUG:** Trimipramine

## Key facts

- **NCT ID:** NCT02237937
- **Lead sponsor:** HolsboerMaschmeyer NeuroChemie GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2014-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02237937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02237937, "Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02237937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*